Orexo US, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$331Kgeneral payments (2019-2025)
$3.6Mresearch payments (2019-2025)
4,580clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Mohammad Kabir | Troy, NY | Addiction Medicine (Internal Medicine) | $6,695.84 |
| Robert Masone | Columbus, OH | Addiction Medicine (Anesthesiology) | $5,851.94 |
| Michael Fox | Livonia, MI | Addiction Medicine (Family Medicine) | $3,708.47 |
| Timothy Gammons | Sterling Heights, MI | Addiction Medicine (Family Medicine) | $3,591.83 |
| Jeanette Moleski | Hudson, OH | Family Medicine | $3,239.64 |
| Mohd Malik | Saint Louis, MO | Psychiatry | $3,123.07 |
| Matthew Torrington | Culver City, CA | Addiction Medicine (Family Medicine) | $2,347.52 |
| Lance Austein | Brooklyn, NY | Internal Medicine | $2,091.83 |
| Amit Vijapura | Jacksonville, FL | Psychiatry | $1,870.75 |
| Jeffrey Summe | Lynnwood, WA | Family Medicine | $1,705.02 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.